Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Harvard Bioscience's
Operating Income
for the
three
months ended in Mar. 2026 was €-0.81 Mil. Harvard Bioscience's Interest Expense for the
three
months ended in Mar. 2026 was €-1.50 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Harvard Bioscience Incs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
The historical rank and industry rank for Harvard Bioscience's Interest Coverage or its related term are showing as below:
FRA:HBI0'
s Interest Coverage Range Over the Past 10 Years
Min: 0.02 Med: 0.26 Max: 1.34
Current: 0.11
FRA:HBI0's Interest Coverage is ranked worse than 99.36% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 15.71
vs FRA:HBI0: 0.11
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Harvard Bioscience Interest Coverage Related Terms
Harvard Bioscience Interest Coverage Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:HBI0 vs FEMY, RVP, MLSS: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Harvard Bioscience did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Harvard Bioscience (FRA:HBI0) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Harvard Bioscience and its competitors. Over the past decade, Harvard Bioscience's Interest Coverage has ranged from 0.02 to 1.34. According to the industry distribution chart, Harvard Bioscience ranks #465 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 99.4%.
Is Harvard Bioscience's Interest Coverage too high?
Harvard Bioscience's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.34. Based on the distribution chart, Harvard Bioscience ranks #465 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Interest Coverage compare to FEMY and RVP?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #465 out of 468 companies for Interest Coverage. This places Harvard Bioscience in the lower half of its industry. The industry median Interest Coverage is 15.71. Historically, Harvard Bioscience's own Interest Coverage has ranged from 0.02 to 1.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.71, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Interest Coverage of 0 (At Loss). The stock's GF Value™ is €13.11, compared to a current price of €4.08 — trading 68.9% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 68.9% below its estimated GF Value™ of €13.11.
Key valuation signals for FRA:HBI0:
Interest Coverage: 0 (At Loss)
GF Value™: €13.11 vs. price of €4.08 (68.9% below fair value)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score
Get the complete analysis for FRA:HBI0
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
